INY-03-041 trihydrochloride

INY-03-041 trihydrochloride

Target: INY-03-041 trihydrochloride targets AKT1, AKT2, and AKT3 kinase isoforms.

Binding site: Its ipatasertib warhead binds the ATP-competitive catalytic pocket of AKT kinases.

Mechanism of action: INY-03-041 trihydrochloride is the trihydrochloride salt form of a selective pan-AKT PROTAC degrader. It combines the ATP-competitive AKT inhibitor ipatasertib with the cereblon ligand lenalidomide, enabling recruitment of AKT1, AKT2, and AKT3 to CRL4CRBN ubiquitin ligase machinery. This proximity-driven mechanism promotes AKT ubiquitination and proteasome-mediated degradation, producing sustained suppression of downstream AKT signaling beyond reversible kinase inhibition. The compound is useful for studying AKT isoform dependency, pathway durability, degradation kinetics, and concentration-dependent degradation behavior in PI3K/AKT pathway models.

• PROTAC-Mediated Kinase Degradation: INY-03-041 trihydrochloride is utilized in research to selectively degrade kinase proteins, enabling the study of kinase signaling pathways. This aids in understanding the role of specific kinases in cellular processes and disease mechanisms, providing insights into potential therapeutic targets.

• Targeted Protein Degradation in Oncology: Researchers apply INY-03-041 trihydrochloride to investigate the degradation of oncogenic proteins. This application is crucial for exploring novel cancer treatment strategies by eliminating proteins that drive tumor growth and survival.

• Investigating Protein-Protein Interactions: By facilitating the targeted degradation of specific proteins, INY-03-041 trihydrochloride helps elucidate protein-protein interactions within cells. This application is vital for mapping interaction networks and understanding the functional consequences of disrupting these interactions.

• PROTAC-Induced Protein Knockdown: INY-03-041 trihydrochloride enables researchers to achieve precise protein knockdown, offering a powerful tool for studying protein function and validating drug targets. This approach is essential for dissecting complex biological pathways and identifying potential intervention points.